Business Context and Reporting Period
This Form 8-K Current Report was filed by NewAmsterdam Pharma Company N.V. on September 2, 2025. The registrant is incorporated in The Netherlands and lists its ordinary shares (NAMS) and warrants (NAMSW) on The Nasdaq Stock Market LLC. The filing serves as a Regulation FD disclosure regarding the release of an updated corporate investor presentation.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate presentation rather than a financial statement containing quantitative performance data.
Material Changes
No material financial changes versus a prior comparable period are detailed in this document. The primary event reported is the posting of an updated corporate investor presentation on the company's website.
Guidance, Outlook, and Risks
Management Commentary: The company furnished an updated corporate investor presentation (Exhibit 99.1) to the market.
Legal Status of Information: The information contained in the presentation is "furnished" and not "filed" under the Securities Exchange Act of 1934. Consequently, it is not subject to the liability of Section 18 of the Exchange Act or Sections 11 and 12(a)(2) of the Securities Act of 1933. The content is not incorporated by reference into other filings unless expressly stated.
Key Facts for Investor Verification
- Verify the content of the Corporate Investor Presentation (Exhibit 99.1) dated September 2, 2025, for specific operational updates or strategic shifts.
- Note that the presentation is not incorporated by reference into this 8-K filing and carries different liability standards than filed financial statements.
- Confirm the company's current stock ticker symbols: NAMS (Ordinary Shares) and NAMSW (Warrants).
- Review the company's website directly for the full presentation, as the 8-K only references its existence.